Bristol-Myers Squibb acquires Cormorant Pharmaceuticals
Bristol-Myers Squibb Company and Cormorant Pharmaceuticals announced that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, Stockholm, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases. The ... more
Bristol-Myers Squibb names Peter J. Arduini to board of directors
Bristol-Myers Squibb Company announced that its Board of Directors has elected Peter J. Arduini to the Board, effective April 1, 2016. Mr. Arduini will serve as a member of the Audit Committee of the Board of Directors, effective May 3, 2016.
Mr. Arduini, 51, is currently president and chie ... more
Phase 2a Study of HIV-1 Investigational Maturation Inhibitor
Bristol-Myers Squibb Company announced overall antiviral activity and safety results from the three-part Phase 2a proof-of-concept study of BMS-955176, a novel investigational therapy designed to prevent the maturation of HIV-1.The study findings support the continued development of BMS-955 ... more